立体定向体部放疗治疗局部晚期胰腺癌:19项试验的系统综述与汇总分析
该系统综述与汇总分析纳入19项研究共1009例局部晚期胰腺癌患者,评估立体定向体部放疗(SBRT)的疗效与安全性。汇总1年总生存率为51.6%,1年局部区域控制率为72.3%,严重不良事件发生率不超过10%。SBRT是治疗不可手术胰腺癌的有效选择,但仍需大型随机研究验证。
要点
- 汇总1年总生存率为51.6%,中位总生存期范围为5.7至47个月(中位17个月)。
- 1年局部区域控制率为72.3%,且局部区域控制似与SBRT总剂量和分次数相关。
- 严重不良事件发生率不超过10%,但证据受非随机研究和小样本单中心限制。
核心结论
- SBRT在治疗时间、总生存和局部区域控制方面的优势表明,其是不可手术胰腺癌的有效选择。
- 由于纳入研究为非随机设计且多为小样本单中心混合人群,仍需大型随机研究对该治疗模式进行确定性验证。
研究设计与样本
- 系统检索Cochrane中心对照试验注册库、PubMed、EMBASE、SCOPUS、Web of Science和CINAHL中关于SBRT治疗局部晚期胰腺癌的文献。
- 共纳入19项研究、1009例患者,采用多变量随机效应荟萃分析计算汇总生存率与局部控制率。
- 主要终点为1年总生存率,次要终点包括中位总生存期、2年总生存率、1年局部区域控制率和3至4级毒性。
主要发现
- 13项有数据的试验汇总1年总生存率为51.6%。
- 中位总生存期范围为5.7至47个月(中位17个月)。
- 1年局部区域控制率为72.3%。
- 总体严重不良事件发生率不超过10%。
- 局部区域控制似与SBRT总剂量和分次数相关。
临床怎么用
- 对于不可手术的局部晚期胰腺癌,SBRT可作为聚焦局部治疗的有效选择之一。
- 临床决策时需结合SBRT总剂量与分次数对局部区域控制的潜在影响。
局限性
- 纳入研究均为非随机研究。
- 多数为小样本单中心系列且纳入混合人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although surgery is the standard of care for resectable pancreatic cancer (PC), standard-dose chemoradiation therapy and chemotherapy alone are suitable for patients with unresectable disease. Stereotactic body radiation therapy (SBRT) is an alternative, focused local therapy that delivers high radiation doses within a few fractions to the cancer, sparing the surrounding critical tissue. We performed a systematic review and pooled analysis of published trials to evaluate the efficacy and safety of this emerging treatment modality. METHODS AND MATERIALS: We searched the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, SCOPUS, the Web of Science, and CINAHL for publications regarding SBRT for locally advanced PC. The 1-year overall survival (OS) rate was the primary endpoint, and the median OS, 2-year OS rate, 1-year locoregional control (LRC) rate, and grade 3 to 4 toxicities were the secondary endpoints. A multivariate random-effects meta-analysis was performed to calculate the aggregated OS rates at 1 and 2 years and the 1-year LRC rate. RESULTS: A total of 19 studies, encompassing 1009 patients, were included in the present analysis. The pooled 1-year OS was 51.6% in 13 trials with data available. The median OS ranged from 5.7 to 47 months (median 17). The LRC rate at 1 year was 72.3%. Overall, the occurrence of severe adverse events did not exceed 10%. LRC appeared to correlate with the total SBRT dose and the number of fractions. CONCLUSIONS: The advantages of SBRT in terms of treatment time, satisfactory OS, and LRC indicate that it is an effective option for inoperable PC. However, a definitive validation of this treatment modality in large randomized studies is required, owing to the nonrandomized nature of the included studies and the limitations of small single-center series that include mixed populations.
引用
- Petrelli F, Comito T, Ghidini A, et al. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys. 2016. PMID: 28068239. doi:10.1016/j.ijrobp.2016.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。